Document Detail

Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients.
MedLine Citation:
PMID:  23372341     Owner:  NLM     Status:  PubMed-not-MEDLINE    
The purpose of this study was to identify and validate circulating microRNAs (miRNAs) in human plasma for use as breast cancer (BC) biomarkers and to analyze their relationship to clinicopathologic features and its preliminary biological function. Genome-wide expression profiling of miRNAs in BC was investigated by microarray analysis. miR-155 was up-regulated greater than two-fold in BC compared with Normal Adjacent Tissue (NAT), whereas let-7b, miR-381, miR-10b, miR-125a-5p, miR-335, miR-205 and miR-145 were down- regulated greater than two-fold. Our hypothesis was that circulating miRNAs are also present and differentially expressed in the serum of BC patients compared to controls. Using real-time PCR (RT-PCR), we analyzed miR-205 and miR-155 in archived serum from 30 participants, 20 with breast cancer and 10 healthy people. miR-205 was down-regulated in BC patient serum while miR-155 was up-regulated. Furthermore, we analyzed the relationship between the expression levels of these two miRNAs and the clinicopathologic parameters of BC patients. High expression of miR155 was associated with clinical stage, molecular type, Ki-67 and p53 in BC patients (P<0.05). By contrast, we found no significant correlation between miR-205 and BC patient clinicopathologic parameters. Functional analysis showed that ectopic expression of miR-205 significantly inhibits cell proliferation and promotes apoptosis. miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum. miR-155 was positive correlated with clinical stage and ki-67 and negatively correlated with p53 status.
Jingjing Liu; Qixin Mao; Yan Liu; Xiaomeng Hao; Sheng Zhang; Jin Zhang
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chinese journal of cancer research = Chung-kuo yen cheng yen chiu     Volume:  25     ISSN:  1000-9604     ISO Abbreviation:  Chin. J. Cancer Res.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-01     Completed Date:  2013-02-04     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  9315242     Medline TA:  Chin J Cancer Res     Country:  China    
Other Details:
Languages:  eng     Pagination:  46-54     Citation Subset:  -    
3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research center, Tianjin Medical University Institute and Hospital, Tianjin, China; ; Key laboratory of breast cancer prevention and therapy of ministry of education, Tianjin, China; ; Key laboratory of cancer prevention and therapy in Tianjin, Tianjin, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnosis of breast cancer by tissue analysis.
Next Document:  Current diagnostic approach to patients with adnexal masses: which tools are relevant in routine pra...